New genomic landscapes and therapeutic targets for biliary tract cancers

Frontiers in Bioscience - Landmark

Volumn 21, Issue 4, 2016, Pages 707-718

  Simbolo, Michele ^a   Fassan, Matteo ^a   Mafficini, Andrea ^a   Lawlor, Rita T ^b   Ruzzenente, Andrea ^a   Scarpa, Aldo ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

Author keywords

Cholangiocarcinoma; Molecular Profiling; Review; Targeted Therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

BILIARY TRACT NEOPLASMS; CELL CYCLE; CELL SURVIVAL; GENETICS; HUMAN; INFLAMMATION; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; CELL CYCLE; CELL SURVIVAL; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION;

EID: 85016128376     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4416     Document Type: Review

References (79)

1. Y Shaib, HB El-Serag: The epidemiology of cholangiocarcinoma. Semin Liver Dis 24, 115-125 (2004) DOI: 10.1055/s-2004-828889
2. T Patel: Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol 8, 189-200 (2011) DOI: 10.1038/nrgastro.2011.20
3. AE Sirica: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41, 5-15 (2005) DOI: 10.1002/hep.20537
4. T Patel: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2, 10 (2002) DOI: 10.1186/1471-2407-2-10
5. KN Lazaridis, GJ Gores: Cholangiocarcinoma. Gastroenterology 128, 1655-1667 (2005) DOI: 10.1053/j.gastro.2005.03.040
6. SA Khan, HC Thomas, BR Davidson, SD Taylor-Robinson: Cholangiocarcinoma. Lancet 366, 1303-1314 (2005) DOI: 10.1016/S0140-6736(05)67530-7
7. DJ van Leeuwen, JW Reeders: Primary sclerosing cholangitis and cholangiocarcinoma as a diagnostic and therapeutic dilemma. Ann Oncol 10 Suppl 4, 89-93 (1999) DOI: 10.1093/annonc/10.suppl-4.S89
8. PC de Groen, GJ Gores, NF LaRusso, LL Gunderson, DM Nagorney: Biliary tract cancers. NEJM 341, 1368-1378 (1999) DOI: 10.1056/NEJM199910283411807
9. M Jaiswal, NF LaRusso, LJ Burgart, GJ Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60, 184-190 (2000)
10. JS Goydos, AM Brumfield, E Frezza, A Booth, MT Lotze, SE Carty. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 227, 398-404 (1998) DOI: 10.1097/00000658-199803000-00012
11. P Tangkijvanich, D Thong-ngam, A Theamboonlers, O Hanvivatvong, P Kullavanijaya, Y Poovorawan: Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma. Hepatogastroenterology 51, 15-19 (2004)
12. K Okada, Y Shimizu, S Nambu, K Higuchi, A Watanabe: Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 9, 462-467 (1994) DOI: 10.1111/j.1440-1746.1994.tb01275.x
13. F Meng, Y Yamagiwa, Y Ueno, T Patel: Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol 44, 1055-1065 (2006) DOI: 10.1016/j.jhep.2005.10.030
14. Y Yamagiwa, F Meng, T Patel: Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. Life Sci 78, 2494-2502 (2006) DOI: 10.1016/j.lfs.2005.10.015
15. H Isomoto, S Kobayashi, NW Werneburg, SF Bronk, ME Guicciardi, DA Frank, GJ Gores: Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42, 1329-1338 (2005) DOI: 10.1002/hep.20966
16. H Dokduang, A Techasen, N Namwat, N Khuntikeo, C Pairojkul, Y Murakami, W Loilome, P Yongvanit: STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression. J Hepatobiliary Pancreat Sci 21, 767-776 (2014) DOI: 10.1002/jhbp.131
17. JH Yoon, AE Canbay, NW Werneburg, SP Lee, GJ Gores: Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 39, 732-738 (2004) DOI: 10.1002/hep.20125
18. N Ishimura, SF Bronk, GJ Gores: Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol 287, G88-95 (2004) DOI: 10.1152/ajpgi.00539.2003
19. S Aishima, Y Mano, Y Tanaka, Y Kubo, K Shirabe, Y Maehara, Y Oda: Different roles of inducible nitric oxide synthase and cyclooxygenase-2 in carcinogenesis and metastasis of intrahepatic cholangiocarcinoma. Hum Pathol 44, 1031-1037 (2013) DOI: 10.1016/j.humpath.2012.09.004
20. W Chan-On, ML Nairismagi, CK Ong, WK Lim, S Dima, C Pairojkul, KH Lim, JR McPherson, I Cutcutache, HL Heng, L Ooi, A Chung, P Chow, PC Cheow, SY Lee, SP Choo, IB Tan, D Duda, A Nastase, SS Myint, BH Wong, A Gan, V Rajasegaran, CC Ng, S Nagarajan, A Jusakul, S Zhang, P Vohra, W Yu, D Huang, P Sithithaworn, P Yongvanit, S Wongkham, N Khuntikeo, V Bhudhisawasdi, I Popescu, SG Rozen, P Tan, BT The: Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 45, 1474-1478 (2013) DOI: 10.1038/ng.2806
21. D Lee, IG Do, K Choi, CO Sung, KT Jang, D Choi, JS Heo, SH Choi, J Kim, JY Park, HJ Cha, JW Joh, KY Choi, DS Kim: Theexpression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol 25, 131-139 (2012) DOI: 10.1038/modpathol.2011.133
22. M Simbolo, M Fassan, A Ruzzenente, A Mafficini, LD Wood, V Corbo, D Melisi, G Malleo, C Vicentini, G Malpeli, D Antonello, N Sperandio, P Capelli, A Tomezzoli, C Iacono, RT Lawlor, C Bassi, RH Hruban, A Guglielmi, G Tortora, F de Braud, A Scarpa A. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 5, 2839-2852 (2014)
23. B Herberger, H Puhalla, M Lehnert, F Wrba, S Novak, A Brandstetter, B Gruenberger, T Gruenberger, R Pirker, M Filipits: Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 13, 4795-4799 (2007) DOI: 10.1158/1078-0432.CCR-07-0738
24. JY Chung, SM Hong, BY Choi, H Cho, E Yu, SM Hewitt: The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 15, 660-667 (2009) DOI: 10.1158/1078-0432.CCR-08-1084
25. RF Xu, JP Sun, SR Zhang, GS Zhu, LB Li, YL Liao, JM Xie, WJ Liao: KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother 65, 22-26 (2011) DOI: 10.1016/j.biopha.2010.06.009
26. MO Riener, M Bawohl, PA Clavien, W Jochum: Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 47, 363-367 (2008) DOI: 10.1002/gcc.20540
27. R Roskoski Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319, 1-11 (2004) DOI: 10.1016/j.bbrc.2004.04.150
28. N Normanno, C Bianco, L Strizzi, M Mancino, MR Maiello, A De Luca, F Caponigro, DS Salomon: The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6, 243-257 (2005) DOI: 10.2174/1389450053765879
29. K Nakazawa, Y Dobashi, S Suzuki, H Fujii, Y Takeda, A Ooi: Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206, 356-365 (2005) DOI: 10.1002/path.1779
30. Y Ito, T Takeda, Y Sasaki, M Sakon, T Yamada, S Ishiguro, S Imaoka, M Tsujimoto, S Higashiyama, M Monden, N Matsuura: Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 197, 95-100 (2001) DOI: 10.1078/0344-0338-00016
31. A Nonomura, G Ohta, Y Nakanuma, R Izumi, Y Mizukami, F Matsubara, M Hayashi, K Watanabe, N Takayanagi: Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 8, 157-166 (1988) DOI: 10.1111/j.1600-0676.1988.tb00985.x
32. A Altimari, M Fiorentino, E Gabusi, E Gruppioni, B Corti, A D'Errico, WF Grigioni: Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig LiverDis 35, 332-338 (2003) DOI: 10.1016/S1590-8658(03)00077-X
33. EM Brunt, PE Swanson: Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver. Am J Clin Pathol 97, S53-61 (1992)
34. SI Aishima, KI Taguchi, K Sugimachi, M Shimada, M Tsuneyoshi: c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 40, 269-278 (2002) DOI: 10.1046/j.1365-2559.2002.00353.x
35. K Endo, BI Yoon, C Pairojkul, AJ Demetris, AE Sirica: ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36, 439-450 (2002) DOI: 10.1053/jhep.2002.34435
36. WC Su, SC Shiesh, HS Liu, CY Chen, NH Chow, XZ Lin: Expression of oncogene products HER2/Neu and Ras and fibrosisrelated growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignanciesand inflammatory disorders. Dig Dis Sci 46, 1387-1392 (2001) DOI: 10.1023/A:1010619316436
37. F Leone, G Cavalloni, Y Pignochino, I Sarotto, R Ferraris, W Piacibello, T Venesio, L Capussotti, M Risio, M Aglietta: Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 12, 1680-1685 (2006) DOI: 10.1158/1078-0432.CCR-05-1692
38. GY Gwak, JH Yoon, CM Shin, YJ Ahn, JK Chung, YA Kim, TY Kim, HS Lee: Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 131, 649-652 (2005) DOI: 10.1007/s00432-005-0016-1
39. M Li, Z Zhang, X Li, J Ye, X Wu, Z Tan, C Liu, B Shen, XA Wang, W Wu, D Zhou, D Zhang, T Wang, B Liu, K Qu, Q Ding, H Weng, J Mu, Y Shu, R Bao, Y Cao, P Chen, T Liu, L Jiang, Y Hu, P Dong, J Gu, W Lu, W Shi, J Lu, W Gong, Z Tang, Y Zhang, X Wang, YE Chin, X Weng, H Zhang, W Tang, Y Zheng, L He, H Wang, Y Liu: Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 46, 872-876 (2014) DOI: 10.1038/ng.3030
40. T Ueki, J Fujimoto, T Suzuki, H Yamamoto, E Okamoto: Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 25, 862-866 (1997) DOI: 10.1002/hep.510250413
41. T Terada, Y Nakanuma, AE Sirica: Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 29, 175-180 (1998) DOI: 10.1016/S0046-8177(98)90229-5
42. M Goggins, M Shekher, K Turnacioglu, CJ Yeo, RH Hruban, SE Kern: Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 58, 5329-5332 (1998)
43. M Nagai, Y Kawarada, M Watanabe, T Iwase, T Muneyuki, K Yamao, K Fukutome, R Yatani: Analysis of microsatellite instability, TGF-beta type II receptor gene mutations and hMSH2 and hMLH1 allele losses in pancreaticobiliary maljunction-associated biliary tract tumors. Anticancer Res 19, 1765-1768 (1999)
44. S Yazumi, K Ko, N Watanabe, H Shinohara, K Yoshikawa, T Chiba, R Takahashi: Disrupted transforming growth factor-beta signaling and deregulated growth in human biliary tract cancer cells. Int J Cancer 86, 782-789 (2000) DOI: 10.1002/(SICI)1097-0215(20000615) 86:6782: AID-IJC53.0.CO;2-O
45. N Turner, R Grose. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10, 116-129 (2010) DOI: 10.1038/nrc2780
46. Y Arai, Y Totoki, F Hosoda, T Shirota, N Hama, H Nakamura, H Ojima, K Furuta, K Shimada, T Okusaka, T Kosuge, T Shibata: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59, 1427-1434 (2014) DOI: 10.1002/hep.26890
47. YM Wu, F Su, S Kalyana-Sundaram, N Khazanov, B Ateeq, X Cao, RJ Lonigro, P Vats, R Wang, SF Lin, AJ Cheng, LP Kunju, J Siddiqui, SA Tomlins, P Wyngaard, S Sadis, S Roychowdhury, MH Hussain, FY Feng, MM Zalupski, M Talpaz, KJ Pienta, DR Rhodes, DR Robinson, AM Chinnaiyan: Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3, 636-647 (2013) DOI: 10.1158/2159-8290.CD-13-0050
48. II Wistuba, AF Gazdar: Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 4, 695-706 (2004) DOI: 10.1038/nrc1429
49. M Watanabe, M Asaka, J Tanaka, M Kurosawa, M Kasai, T Miyazaki: Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology 107, 1147-1153 (1994)
50. K Ohashi, Y Nakajima, H Kanehiro, M Tsutsumi, J Taki, Y Aomatsu, A Yoshimura, S Ko, T Kin, K Yagura K: Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 109, 1612-1617 (1995) DOI: 10.1016/0016-5085(95)90650-9
51. YK Kang, WH Kim, HW Lee, HK Lee, YI Kim: Mutation of p53 and K-ras, and lossof heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 79, 477-483 (1999)
52. J Albores-Saavedra, NV Adsay, JM Crawford JM, et al. Carcinoma of the gallbladder and extrahepatic bile ducts. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Eds: FT Bosman, F Carneiro, RH Hruban, ND Theise. IARC Press: Lyon (2010)
53. A Tannapfel, F Sommerer, M Benicke, A Katalinic, D Uhlmann, H Witzigmann, J Hauss, C Wittekind: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52, 706-712 (2003) DOI: 10.1136/gut.52.5.706
54. AA Saetta, P Papanastasiou, NV Michalopoulos, F Gigelou, P Korkolopoulou, T Bei, E Patsouris: Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 445, 179-182 (2004) DOI: 10.1007/s00428-004-1046-9
55. SC Chuang, KT Lee, KB Tsai, PC Sheen, E Nagai, K Mizumoto, M Tanaka: Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg 28, 995-1000 (2004) DOI: 10.1007/s00268-004-7447-8
56. SA Hahn, D Bartsch, A Schroers, H Galehdari, M Becker, A Ramaswamy, I Schwarte-Waldhoff, H Maschek, W Schmiegel: Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 58, 1124-1126 (1998)
57. X Xu, S Kobayashi, W Qiao, C Li, C Xiao, S Radaeva, B Stiles, RH Wang, N Ohara, T Yoshino, D LeRoith, MS Torbenson, GJ Gores, H Wu, B Gao, CX Deng: Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 116, 1843-1852 (2006) DOI: 10.1172/JCI27282
58. CJ Sherr: Cancer cell cycles. Science 274, 1672-1677 (1996) DOI: 10.1126/science.274.5293.1672
59. WR Jarnagin, DS Klimstra, M Hezel, M Gonen, Y Fong, K Roggin, K Cymes, RP DeMatteo, M D'Angelica, LH Blumgart, B Singh: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 24, 1152-1160 (2006) DOI: 10.1200/JCO.2005.04.6631
60. A Ishikawa, M Sasaki, Y Sato, S Ohira, MF Chen, SF Huang, K Oda, Y Nimura, Y Nakanuma: Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis. Hum Pathol 35, 1505-1514 (2004) DOI: 10.1016/j.humpath.2004.08.014
61. AK Virmani, C Muller, A Rathi, S Zoechbauer-Mueller, M Mathis, AF Gazdar: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 7, 584-589 (2001)
62. A Tannapfel, M Benicke, A Katalinic, D Uhlmann, F Kockerling, J Hauss, C Wittekind: Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47, 721-727 (2000) DOI: 10.1136/gut.47.5.721
63. EP Berthiaume, J Wands: The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 24, 127-137 (2004) DOI: 10.1055/s-2004-828890
64. S Furubo, K Harada, T Shimonishi, K Katayanagi, W Tsui, Y Nakanuma: Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 35, 230-240 (1999) DOI: 10.1046/j.1365-2559.1999.00705.x
65. Y Jiao, TM Pawlik, RA Anders, FM Selaru, MM Streppel, DJ Lucas, N Niknafs, VB Guthrie, A Maitra, P Argani, GJ Offerhaus, JC Roa, LR Roberts, GJ Gores, I Popescu, ST Alexandrescu, S Dima, M Fassan, M Simbolo, A Mafficini, P Capelli, RT Lawlor, A Ruzzenente, A Guglielmi, G Tortora, F de Braud, A Scarpa, W Jarnagin, D Klimstra, R Karchin, VE Velculescu, RH Hruban, B Vogelstein, KW Kinzler, N Papadopoulos, LD Wood: Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45, 1470-1473 (2013) DOI: 10.1038/ng.2813
66. S Zhao, Y Lin, W Xu, W Jiang, Z Zha, P Wang, W Yu, Z Li, L Gong, Y Peng, J Ding, Q Lei, KL Guan, Y Xiong: Glioma-derived mutationsin IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324, 261-265 (2009) DOI: 10.1126/science.1170944
67. L Dang, DW White, S Gross, BD Bennett, MA Bittinger, EM Driggers, VR Fantin, HG Jang, S Jin, MC Keenan, KM Marks, RM Prins, PS Ward, KE Yen, LM Liau, JD Rabinowitz, LC Cantley, CB Thompson, MG Vander Heiden, SM Su: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009) DOI: 10.1038/nature08617
68. DR Borger, KK Tanabe, KC Fan, HU Lopez, VR Fantin, KS Straley, DP Schenkein, AF Hezel, M Ancukiewicz, HM Liebman, EL Kwak, JW Clark, DP Ryan, V Deshpande, D Dias-Santagata, LW Ellisen, AX Zhu, AJ Iafrate: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broadbased tumor genotyping. Oncologist 17, 72-79 (2012) DOI: 10.1634/theoncologist.2011-0386
69. PS Ward, J Patel, DR Wise, O Abdel-Wahab, BD Bennett, HA Coller, JR Cross, VR Fantin, CV Hedvat, AE Perl, JD Rabinowitz, M Carroll, SM Su, KA Sharp, RL Levine, CB Thompson: The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alphaketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225-234 (2010) DOI: 10.1016/j.ccr.2010.01.020
70. DR Borger, L Goyal, T Yau, RT Poon, M Ancukiewicz, V Deshpande, DC Christiani, HM Liebman, H Yang, H Kim, K Yen, JE Faris, AJ Iafrate, EL Kwak, JW Clark, JN Allen, LS Blaszkowsky, JE Murphy, SK Saha, TS Hong, JY Wo, CR Ferrone, KK Tanabe, N Bardeesy, KS Straley, S Agresta, DP Schenkein, LW Ellisen, DP Ryan, AX Zhu: Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res 20, 1884-1890 (2014) DOI: 10.1158/1078-0432.CCR-13-2649
71. ML Suva, N Riggi, BE Bernstein: Epigenetic reprogramming in cancer. Science 339, 1567-1570 (2013) DOI: 10.1126/science.1230184
72. I Varela, P Tarpey, K Raine, D Huang, CK Ong, P Stephens, H Davies, D Jones, ML Lin, J Teague, G Bignell, A Butler, J Cho, GL Dalgliesh, D Galappaththige, C Greenman, C Hardy, M Jia, C Latimer, KW Lau, J Marshall, S McLaren, A Menzies, L Mudie, L Stebbings, DA Largaespada, LF Wessels, S Richard, RJ Kahnoski, J Anema, DA Tuveson, PA Perez-Mancera, V Mustonen, A Fischer, DJ Adams, A Rust, W Chan-on, C Subimerb, K Dykema, K Furge, PJ Campbell, BT Teh, MR Stratton, PA Futreal. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011) DOI: 10.1038/nature09639
73. M Thompson: Polybromo-1: The chromatin targeting subunit of the PBAF complex. Biochimie 91, 309-319 (2009) DOI: 10.1016/j.biochi.2008.10.019
74. R Chandrasekaran, M Thompson: Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions. Biochem Biophys Res Commun 355, 661-666 (2007) DOI: 10.1016/j.bbrc.2007.01.193
75. CR Churi, R Shroff, Y Wang, A Rashid, HC Kang, J Weatherly, M Zuo, R Zinner, D Hong, F Meric-Bernstam, F Janku, CH Crane, L Mishra, JN Vauthey, RA Wolff, G Mills, M Javle: Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PloS one 9, e115383 (2014) DOI: 10.1371/journal.pone.0115383
76. D Wilsker, A Patsialou, SD Zumbrun, S Kim, Y Chen, PB Dallas, E Moran: The DNA-binding properties of the ARID-containing subunits of yeast and mammalian SWI/SNF complexes. Nucleic Acids Res 32, 1345-1353 (2004) DOI: 10.1093/nar/gkh277
77. A Bheda, J Shackelford, JS Pagano: Expression and functional studies of ubiquitin C-terminal hydrolase L1 regulated genes. PloS one 4, e6764 (2009) DOI: 10.1371/journal.pone.0006764
78. RA Greenberg, B Sobhian, S Pathania, SB Cantor, Y Nakatani, DM Livingston: Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 20, 34-46 (2006) DOI: 10.1101/gad.1381306
79. H Nishikawa, W Wu, A Koike, R Kojima, H Gomi, M Fukuda, T Ohta: BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 69, 111-119 (2009) DOI: 10.1158/0008-5472.CAN-08-3355